Get the Stockscreener App
4.22
0.71%
-0.03
After Hours:
4.20
-0.02
-0.47%
Geron Corp stock is traded at $4.22, with a volume of 6.00M.
It is down -0.71% in the last 24 hours and down -2.31% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$4.25
Open:
$4.3
24h Volume:
6.00M
Relative Volume:
0.78
Market Cap:
$2.56B
Revenue:
$237.00K
Net Income/Loss:
$-184.13M
P/E Ratio:
-12.41
EPS:
-0.34
Net Cash Flow:
$-168.57M
1W Performance:
-0.94%
1M Performance:
-2.31%
6M Performance:
+7.38%
1Y Performance:
+113.13%
1-Day Range:
$4.12
$4.32
1-Week Range:
$3.98
$4.32
52-Week Range:
$1.64
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
H.C. Wainwright: 'Rytelo off to a strong launch,' assigns Buy to Geron shares - Investing.com
Analyst Ratings For Geron - Benzinga
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies - Yahoo Finance
abrdn plc Acquires New Position in Geron Co. (NASDAQ:GERN) - MarketBeat
Geron (GERN) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
B.Riley sets Geron stock target, sustains Buy on strong Rytelo sales - Investing.com
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Geron (NASDAQ:GERN) Receives New Coverage from Analysts at Scotiabank - MarketBeat
Is Geron Corporation (GERN) the Hottest Penny Stock to Invest in According to Hedge Funds? - Insider Monkey
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan
You might want to take a look at Geron Corp. (GERN) now - SETE News
Geron Corp. [GERN] gain 96.21% so far this year. What now? - The DBT News
Financial Snapshot: Analyzing Geron Corp. (GERN)’s Key Ratio Metrics - The Dwinnex
Geron Corp. [GERN] Insider GRETHLEIN ANDREW J sells 674,348 Shares – Insider Selling Alert - Knox Daily
Geron (NASDAQ:GERN) Shares Down 3%Here's Why - MarketBeat
Geron Corp. (GERN) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Is Geron Corporation (GERN) the Best Growth Stock Under $10 to Buy? - Insider Monkey
Leerink maintains Outperform rating on Geron shares - Investing.com
Leerink maintains Outperform rating on Geron shares By Investing.com - Investing.com UK
Geron Corp. [GERN] Shares Jump Approximately 139.23% Over the Year - Knox Daily
Is Geron Corporation (GERN) the Best Stock Under $10 With High Potential? - Insider Monkey
Geron Corp (GERN) Q2 2024 Earnings Call Highlights: Strong Financial Position Amid Early Rytelo ... - Yahoo Finance
Wall Street Analysts Rate Geron Corporation (GERN) as a Buy Amid Strong Growth Prospects - Insider Monkey
Geron (NASDAQ:GERN) Trading 4.1% HigherTime to Buy? - MarketBeat
Geron Corp. [GERN] Insider GRETHLEIN ANDREW J sells 674,348 Shares – Latest News - Knox Daily
The Manufacturers Life Insurance Company Acquires 553,081 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat
Geron Corporation (GERN): A Hot Stock to Buy Now - Insider Monkey
Algert Global LLC Takes $539,000 Position in Geron Co. (NASDAQ:GERN) - MarketBeat
10 Best Biotech Stocks To Buy Under $20 - Insider Monkey
Goldman Sachs maintains Buy rating on Geron - Investing.com
Is Geron Corporation (GERN) the Best NASDAQ Stock Under $5? - Insider Monkey
High Growth Tech Stocks To Watch This October 2024 - Simply Wall St
When Can We Expect A Profit From Geron Corporation (NASDAQ:GERN)? - Yahoo Finance
Geron's SWOT analysis: biotech firm's stock rides on Rytelo success - Investing.com
Renaissance Technologies LLC Takes $3.32 Million Position in Geron Co. (NASDAQ:GERN) - MarketBeat
7 Best NASDAQ Stocks Under $5 - Insider Monkey
Nasdaq Composite [TR] (XCMP) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
Is This Penny Stock With 55% Upside A Buy Now? - Barchart
Darwin Global Management Ltd. Acquires Shares of 23,915,480 Geron Co. (NASDAQ:GERN) - MarketBeat
Positive early demand trends for Geron’s Rytelo lead Goldman Sachs to reaffirm Buy rating - Investing.com
Check Out Geron Corp. (GERN)’s Trade Data Rather Than the Analysts’ Views - SETE News
Affinity Asset Advisors LLC Sells 1,000,000 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat
Farallon Capital Management LLC Has $71.39 Million Position in Geron Co. (NASDAQ:GERN) - MarketBeat
Regeneron slides as Amgen wins Eylea biosimilar case; RBC still bullish - Investing.com
Groupon (GRPN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Geron: Derisked And Highly Attractive After Approval - Seeking Alpha
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
GERN’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Geron Corp. [GERN] moved down -0.63: Why It’s Important - The DBT News
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):